Indicators

Markets:

News

Latest News about LGVN

Recent news which mentions LGVN

< Previous 1 2 3 4 5 6 7 8 9

...

Longeveron (NASDAQ: LGVN) Announces Positive Top-Line Results For Its Phase 2a Clinical Trial For The Treatment Of Mild Alzheimer's Disease with Lomecel-B™

December 05, 2023

Longeveron (NASDAQ: LGVN) Announces Positive Top-Line Results For Its Phase 2a Clinical Trial For The Treatment Of Mild Alzheimer's Disease with Lomecel-B™

December 05, 2023

Earnings Scheduled For November 10, 2023

November 10, 2023

Earnings Preview: Longeveron

November 09, 2023

Nearly A Third Of Japan's 36 Million Seniors Are At Risk Of Aging Frailty – Could Lomecel-BTM, Longeveron's (NASDAQ: LGVN) Cell Therapy Help?

October 23, 2023

Does Bone Marrow Contain The Keys To Curing Alzheimer's? BioTech Announces Promising Results From Clinical Trial

October 13, 2023

12 Health Care Stocks Moving In Thursday's Pre-Market Session

October 12, 2023

12 Health Care Stocks Moving In Monday's Intraday Session

October 09, 2023

12 Health Care Stocks Moving In Monday's Pre-Market Session

October 09, 2023

12 Health Care Stocks Moving In Friday's Pre-Market Session

October 06, 2023

12 Health Care Stocks Moving In Thursday's Intraday Session

October 05, 2023

Why Accolade Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

October 05, 2023

Longeveron's Alzheimer's Candidate Meets Safety Goal In Mid-Stage Study

October 05, 2023

Longeveron stock jumps on Alzheimer’s trial results

October 05, 2023

12 Health Care Stocks Moving In Friday's Pre-Market Session

September 15, 2023

Roth MKM Analyst Projects An Impressive Price Target Of $15 Over The Next 12 Months For BioRestorative Therapies (NASDAQ: BRTX), Says "Low Valuation Undeserved"

September 14, 2023

Longeveron (NASDAQ: LGVN) Reports 100% 5-Year Survival In Trial For Rare Pediatric Disease HLHS (Compared To 80% Survival In Historical Trials) To Market

September 11, 2023

Upcoming Phase 2 Data Expected For Longeveron's (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer's Sector – What To Look For

September 06, 2023

Why Lands' End Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

August 31, 2023

US Stocks Rise; Initial Jobless Claims Edge Lower

August 31, 2023

12 Health Care Stocks Moving In Thursday's Pre-Market Session

August 31, 2023

As America Grapples With A Deadly Opioid Epidemic, BioRestorative Therapies Is Looking To Treat Chronic Pain Without The Need For Class-A Drugs

August 29, 2023

Earnings Scheduled For August 11, 2023

August 11, 2023

Earnings Preview: Longeveron

August 10, 2023

Longeveron – This Biotech Company Is Using The Body's Own Cells To Fight Age-Related Diseases

August 07, 2023

Longeveron Announces Key Additions To Its Leadership Team And Board As It Gears Up For Phase 2 Trials For Its Lead Drug Candidate For Several Conditions

August 07, 2023

Longeveron – Regenerative Medicine Developer Announces 100% Long Term Survival Rate For Children With HLHS

July 11, 2023

12 Health Care Stocks Moving In Friday's Pre-Market Session

July 07, 2023

HLHS Is A Rare And Serious Congenital Heart Disease With A 33% Neonatal Death Rate — Could Longeveron's Lomecel-B Improve Outcomes?

June 28, 2023

LGVN Stock Earnings: Longeveron Misses EPS, Revenue Estimates

May 12, 2023

< Previous 1 2 3 4 5 6 7 8 9

...

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

© 2025 FinancialContent. All rights reserved.